NDA 21887/S-009

SUPPLEMENT APPROVAL

GlaxoSmithKline Consumer Healthcare
Contact: Peter Kratochvila
VP, Regulatory Lead US and Americas
1500 Littleton Road
Parsippany, New Jersey 07054

Dear Mr. Kratochvila:

Please refer to your Supplemental New Drug Application (sNDA) dated and received November 18, 2016, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for alli™ (orlistat) capsules, 60 mg.

This “Changes Being Effected” sNDA provides for the addition of the antiretrovirals (HIV medicine) drug-drug interaction under the Warnings subheading “Ask a doctor or pharmacist before use if you are” section of the Drug Facts labeling in accordance with the “Changes Being Effected” (CBE-0) Request Letter from the Agency dated September 21, 2016.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling as soon as they are available, but no more than 30 days after they are printed. The final printed labeling must be identical to the alli™ (orlistat) capsules, 60 mg, 120-count Refill Pack carton (bottle), 170-count immediate container (bottle), 170-count Refill Pack carton (bottle), and 170-count backer card submitted on March 8, 2017; and the 60-count immediate container (bottle) and 60-count Starter Pack carton (bottle) submitted on April 7, 2017. The final printed labeling must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

The final printed labeling should be submitted electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Labeling for approved NDA 21887/S-009.” Approval of this submission by FDA is not required before the labeling is used.
**DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call CAPT Janice Adams-King, Safety Regulatory Project Manager, at (301) 796-3713.

Sincerely,

{See appended electronic signature page}

Valerie Pratt, MD
Deputy Director for Safety
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES:
Immediate Container and Carton Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

----------------------------------------------------
VALERIE S PRATT
05/15/2017